1. Dual Senolytics: Quercefit® Quercetin (500 mg) + Fisetin (125 mg)
Why both?
- Different mechanisms: Quercetin targets BCL-2 family proteins; Fisetin works through PI3K/AKT and mTOR pathways
- Broader cell-type coverage: Different senescent cells respond to different senolytics
- Research precedent: Mayo Clinic's pioneering work used combination senolytic therapy
- Quercetin's role: Provides cardiovascular and anti-inflammatory benefits while supporting senolysis
- Fisetin's role: Delivers more potent direct senolytic effect with neuroprotection
The bioavailability advantage: Quercefit®
Cell Primer uses Quercefit®, not standard quercetin. This matters significantly.
Standard quercetin suffers from poor water solubility and low absorption—only about 20% of an administered dose typically reaches the bloodstream. This is why many supplements require high doses (1,000+ mg) to achieve effects.
Quercefit® uses phytosome technology, where quercetin molecules are bound to phospholipids (from sunflower lecithin), creating a complex that's absorbed 20 times more effectively than standard quercetin. The phospholipid acts as a delivery vehicle, helping quercetin dissolve and cross intestinal membranes far more efficiently.
What this means practically:
- 500 mg of Quercefit® ≈ 10,000 mg of standard quercetin in terms of bioavailability
- Achieves therapeutic blood levels at lower doses
- More consistent absorption across individuals
- Better tolerability (no need for mega-doses that can cause digestive issues)
Clinical studies demonstrate that Quercefit® maintains activity for immune support, inflammatory response modulation, and physical performance at these optimized doses.
The synergy: By targeting multiple survival pathways simultaneously with highly bioavailable quercetin plus fisetin, the combination eliminates senescent cells more effectively than either compound alone—while using lower total doses than you'd need with standard quercetin.